Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management [0.03%]
Willem Pieter Brouwer,Luisa Vonghia,Maja Thiele et al.
Willem Pieter Brouwer et al.
Steatotic liver disease (SLD) is a spectrum of highly prevalent liver diseases encountered at many different healthcare levels. Awareness about metabolic dysfunction-associated SLD (MASLD), MetALD (MASLD and increased alcohol intake) and AL...
Therapeutic vaccination strategy targeting the PreS1 region of L-HBsAg for HBV/HDV co-infection [0.03%]
针对HBV/HDV联合感染L-HBsAg的PreS1区域的治疗性疫苗策略
Rebecca A Russell,James Lok,James M Harris et al.
Rebecca A Russell et al.
Background & aims: Achieving functional cure for chronic hepatitis B (CHB) will likely require a combinatorial approach targeting multiple aspects of the complex HBV life cycle and host adaptive immune responses. Here, we...
Systemic Treatment Patterns and Clinical Outcomes in Hepatocellular Carcinoma: A Multicenter Real-World Study from China (STAR-HCC) [0.03%]
中国多中心肝细胞癌系统治疗模式及临床结局的真实世界研究（STAR-HCC）
Benyi He,Wenmin Liao,Zehao Zheng et al.
Benyi He et al.
Background & aims: Systemic therapy for hepatocellular carcinoma (HCC) has evolved rapidly with the introduction of tyrosine kinase inhibitors (TKI), immune checkpoint inhibitors (ICIs), anti-vascular endothelial growth f...
Systemic Treatment Patterns and Clinical Outcomes in Hepatocellular Carcinoma: A Multicenter Real-World Study from China (STAR-HCC) [0.03%]
中国多中心肝细胞癌系统治疗模式及临床结局的真实世界研究(START-HCC)
Benyi He,Wenmin Liao,Zehao Zheng et al.
Benyi He et al.
Background & aims: Systemic therapy for hepatocellular carcinoma (HCC) has evolved rapidly with the introduction of tyrosine kinase inhibitors (TKI), immune checkpoint inhibitors (ICIs), anti-vascular endothelial growth f...
Management of rare primary liver cancers: combined hepato-cholangiocarcinoma and fibrolamellar hepatocellular carcinoma [0.03%]
原发性罕见肝癌的治疗：肝细胞-胆管细胞混合型癌和纤维板层型肝细胞癌
Matteo Gallant,Marie Decraecker,Marianne Ziol et al.
Matteo Gallant et al.
Fibrolamellar hepatocellular carcinoma (FLC) and combined hepatocellular-cholangiocarcinoma (cHCC-CCA) are rare primary liver cancers for which limited evidence is available to guide clinical management. cHCC-CCA could arises in the context...
Genome-scale CRISPR screening uncovers SRSF6 as a target to sensitize hepatocellular carcinoma to radiotherapy [0.03%]
基于基因组规模的CRISPR筛选发现SRSF6是放射治疗敏化肝细胞癌的新靶点
Wenyi Jiang,Xin Sui,Dezuo Dong et al.
Wenyi Jiang et al.
Background & aims: Radiotherapy confers clinical benefits to hepatocellular carcinoma (HCC) patients across all stages, yet its clinical efficacy is limited by radioresistance. This study aimed to identify key regulators ...
EQ-5D Health Utility Gains with Once-Weekly Semaglutide 2.4 mg in People with MASH and F2/F3 Fibrosis: An Analysis of ESSENCE [0.03%]
一次 weekly 2.4 mg semaglutide 在具有 MASH 和 F2/F3 纤维化患者的健康效益：来自 ESSENCE 分析的结果
Margarida Augusto,Robert Bauer,Simon Clancy et al.
Margarida Augusto et al.
Background & aims: Metabolic dysfunction-associated steatohepatitis (MASH) is the progressive form of metabolic dysfunction-associated steatotic liver. It is highly prevalent, particularly among individuals with overweigh...
Sleep Irregularity is Associated with Reduced Wellbeing in Patients with Cirrhosis [0.03%]
睡眠不规律与肝硬化患者幸福感降低有关
Adam P Buckholz,Himel Mallick,Avesh Thuluvath et al.
Adam P Buckholz et al.
Background and aims: Health-related quality of life (HRQoL) is frequently impaired in cirrhosis. Among the most critical components of reduced HRQoL in cirrhosis is disturbed sleep. Despite the importance of sleep in cirr...
HBsAg isoforms predict HBsAg seroclearance and finite treatment in patients with chronic hepatitis B after cessation of long term nucleos(t)ide analogue [0.03%]
慢性乙型肝炎患者长期核苷(酸)类似物治疗停药后表面抗原转换及低复发风险的预测因素分析：基于表面抗原亚型的临床研究
Lung-Yi Mak,Mark Anderson,Rex Wan-Hin Hui et al.
Lung-Yi Mak et al.
Background and aims: We examined the role of HBsAg isoforms to predict HBsAg seroclearance or finite treatment among patients with chronic hepatitis B (CHB) infection who stopped long-term nucleoside analogue (NUC). ...
Long-term outcome of sinusoidal obstruction syndrome secondary to hematopoietic stem cell transplantation [0.03%]
造血干细胞移植后肝小静脉闭塞病的长期预后研究
Edilmar Alvarado-Tapias,Alexandre Sayadi,Lise Bertin et al.
Edilmar Alvarado-Tapias et al.
Background & aims: Sinusoidal obstruction syndrome (SOS) is a potentially severe complication of conditioning regimens in hematopoietic stem cell transplantation (HSCT). Its long-term outcome is unknown. The aim of this s...